Latest Regulatory Clearance News

Australian Strategic Materials Limited (ASM) shareholders are set to vote on a scheme of arrangement for Energy Fuels Inc. to acquire 100% of ASM shares and options, offering a significant premium and exposure to a vertically integrated rare earth supply chain.

Lumos Diagnostics advances US commercial rollout of FebriDx with positive reimbursement data and expanded urgent care adoption ahead of the 2027/28 flu season.

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

Hartshead Resources has sent its Scheme Booklet to shareholders detailing ACAM GP Limited's proposed $40 million acquisition at a significant premium. The Board unanimously backs the all-cash offer, with a shareholder meeting set for 8 June 2026.

Bremworth Limited and Floorscape Limited have pushed back the deadline for their acquisition scheme to 7 August 2026 after the New Zealand Commerce Commission extended its decision date to 29 May. The deal remains contingent on regulatory approval and shareholder consent.

Aland Equity Group (ASX: AEG) reveals advanced talks on a property funds management transaction linked to its chairman, explaining recent unusual share price activity.

Patagonia Lithium has cleared key environmental hurdles for its Formentera and Cilon mines in Argentina, advancing permits for a 1,000 tonne demonstration plant while drilling hits 150m depth at Well 7.

Peel Mining’s scheme of arrangement with Aeris Resources, coupled with the demerger of Spectre Metals, gains strong endorsement from an independent expert, positioning shareholders for exposure to both a copper producer and a zinc-focused explorer.

Pinnacle Investment Management is boosting its stake in Metrics Credit Holdings back to 35%, investing around A$100.5 million. Simultaneously, Korea’s National Pension Service, via Townsend, is increasing its holding to nearly 10%, pending regulatory approval.

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.

Boab Metals has secured a A$236 million syndicated loan and final regulatory approvals, accelerating construction at its Sorby Hills Silver-Lead-Zinc Project with production on track for H2 2027.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.